The Use of Cytotoxic T Cells for the Prevention and Treatment of Epstein-Barr Virus Induced Lymphoma in Transplant Recipients

References

• Miller G. Epstein-Barr Virus. Biology, pathogenesis and medical aspects. Virology, B N Fields, D M Knipe. Raven Press Ltd, New York 1990; 1921
   Google Scholar
• Rickinson A B, Moss D J. Human cytotoxic T lymphocyte responses to Epstein-Barr virus infection. Annu. Rev. Immunol. 1997; 15: 405
   PubMed Web of Science ®Google Scholar
• Murray R J, Kurilla M G, Brooks J M, Thomas W A, Rowe M, Kieff E., Rickinson A B. Identification of target antigens for the human cytotoxic T cell response to Epstein-Barr virus (EBV): Implications for the immune control of EBV-positive malignancies. J Exp Med 1992; 176: 157
   PubMed Web of Science ®Google Scholar
• Khanna R, Burrows S R, Kurilla M G, Jacob C A, Misko I S, Sculley T B, Kieff E, Moss D J. Localization of Epstein-Barr virus cytotoxic T cell epitopes using recombinant vaccinia: Implications for vaccine development. J Exp Med 1992; 176: 169
   PubMed Web of Science ®Google Scholar
• Babcock G J, Decker L L, Volk M, Thorley-Lawson D A. EBV persistence in memory B cells in vivo. Immunity, 9: 395–108
   PubMed Web of Science ®Google Scholar
• Niedobitek G, Young L S. Epstein-Barr virus persistence and virus-associated tumours [see comments]. Lancet 1994; 343: 333
   PubMed Web of Science ®Google Scholar
• Hanto D W, Frizzera G, Gajl-Peczalska K J, Simmons R L. Epstein-Barr virus, immunodeficiency, and B cell lymphoproliferation. Transplantation 1985; 39: 461
   PubMed Web of Science ®Google Scholar
• Hanto D W, Gajl-Peczalska K J, Frizzera G, Arthur D C, Balfour H HJ, McClain K, Simmons R L, Najarian J S. Epstein-Barr virus (EBV) induced polyclonal and monoclonal B-cell lymphoproliferative diseases occurring after renal transplantation. Clinical, pathologic, and virologic findings and implications for therapy. Ann Surg 1983; 198: 356
   PubMed Web of Science ®Google Scholar
• Shapiro R, Nalesnik M, McCauley J, Fedorek S., Jordan M L, Scantlebury V P, Jain A, Vivas C, Ellis Lombardozzi D., Lane S, Randhawa P, Johnston J, Hakala T R, Simmons R L, Fung J J, Starzl T E. Posttransplant lymphoproliferative disorders in adult and pediatric renal transplant patients receiving tacrolimus-based immunosuppression. Transplantation 1999; 68: 1851
   PubMed Web of Science ®Google Scholar
• Cohen J I. Epstein-Barr virus lymphoproliferative disease associated with acquired immunodeficiency. Medicine 1991; 70: 137
   PubMed Web of Science ®Google Scholar
• Montone K T, Litzky L A, Wurster A, Kaiser L, Bavar J, III, Kotloff R, Palevsky H, Pietra G G, Tomaszewski J E. Analysis of Epstein-Barr virus-associated posttransplantation lymphoproliferative disorder after lung transplantation. Surgery 1996; 119: 544
   PubMed Web of Science ®Google Scholar
• Swinnen L J. Overview of posttransplant B-cell lymphoproliferative disorders. Semin Oncol 1999; 26: 21
   PubMed Web of Science ®Google Scholar
• Paya C V, Fung J J, Nalesnik M A, Kieff E, Green M, Gores G, Habermann T M, Wiesner P H, Swinnen I L, Woodle E S, Bromberg J S. Epstein-Barr virus-induced posttransplant lymphoproliferative disorders. ASTS/ASTP EBV-FTLD Task Force and The Mayo Clinic Organized International Consensus Development Meeting. Transplantation 1999; 68: 1517
   Google Scholar
• Todo S, Tzakis A, Reyes J, Abu-Elmapd K, Furukawa H, Fung K, Starzl T E. Intestinal transplantation: 4-year experience. Transpl Roc 1995; 27: 1355
   PubMed Web of Science ®Google Scholar
• Swinnen L J, Costanzo-Nordin M R, Fisher S G, O'Sullivan El, Johnson M R, Heroux A L, Dizikes G J, Pifarre R, Fisher R I. Increased incidence of lymphoproliferative disorder after immunosuppression with the monoclonal antibody OKT3 in cardiac-transplant recipients. N. Engl. J. Med. 1990; 323: 1723
   PubMed Web of Science ®Google Scholar
• Sokal E M, Antunes H, Beguin C, Bodeus M, Wallemacq P, de Ville D, Reding R, Janssen M, Buts J P, Otte J B. Early signs and risk factors for the increased incidence of Epstein-Barr virus-related posttransplant lymphoproliferative diseases in pediatric liver transplant recipients treated with tacrolimus. Transplantation 1997; 64: 1438
   PubMed Web of Science ®Google Scholar
• Ho M, Miller G, Atchison R W, Breinig M K, Dummer J S, Andiman W, Starzl T E, Eastman R, Griffith B P, Hardesty R L. Epstein-Barr virus infections and DNA hybridization studies in posttransplantation lymphoma and lymphoproliferative lesions: the role of primary infection. J Infect Dis 1985; 152: 876
   PubMed Web of Science ®Google Scholar
• Aris R M, Maia D M, Neuringer I P, Gott K, Kiley S, Gertis K, Handy J. Post-transplantation lymphoproliferative disorder in the Epstein-Barr virus-naive lung transplant recipient. Am J Respir Crit Care Med 1996; 154: 1712
   PubMed Web of Science ®Google Scholar
• Deeg H J, Socie G. Malignancies after hemopoietic stem cell transplantation: Many questions, some answers. Blood 1998; 91: 1833
   PubMed Web of Science ®Google Scholar
• Gross T G, Steinbuch M, De For T, Shapiro R, Mc S., Glave P, Ramsay N KC, Wagner J E, Filipovich A H. B cell lymphoproliferative disorders following hematopoietic stem cell transplantation: Risk factors, treatment and outcome. Bone Marrow Transplant 1999; 23: 251
   PubMed Web of Science ®Google Scholar
• O'Reilly R J, Small T N, Papadopoulos E, Lucas K, Lacerda J, Koulova L. Biology and adoptive cell therapy of Epstein-Barr virus-associated lymphoproliferative disorders in recipients of marrow allografts. Immunological Reviews 1997; 157: 195
   PubMed Web of Science ®Google Scholar
• Heslop H E, Rooney C M. Adoptive Immunotherapy of EBV Lymphoproliferative Disease. Immunological Reviews 1907; 157: 217
   Web of Science ®Google Scholar
• Lucas K G, Burton R L, Zimmerman S E, Wang J., Cornetta K G, Robertson K A, Lee C H, Emanuel D J. Semiquantitative Epstein-Barr virus (EBV) polymerase chain reaction for the determination of patients at risk for EBV-induced lymphoproliferative disease after stem cell transplantation. Blood 1998; 91: 3654
   PubMed Web of Science ®Google Scholar
• Lucas K, Small T, Heller G, Dupont R, O'Reilly R J. The development of cellular immunity to Epstein-Barr virus alter allogeneic bone marrow transplantation. Blood 1996; 87: 2594
   PubMed Web of Science ®Google Scholar
• Small T N, Papadopoulos E B, Boulod F, Black P, Castro-Malaspina H, Childs B H, Collins N, Gillio A, George D, Jakubowski A, Heller G, Fazzari M, Kernan N, MacKinnon Szaboles S. P, Young J W, O'Reilly R J. Comparison of immune reconstitution after nrelated and related T-cell-depleted hone marrow transplantation: effect of patient age and donor leukoeyte infusions. Blood 1999; 93: 467
   PubMed Web of Science ®Google Scholar
• Starzl T E, Naleskin M A, Porter K A, Ho M, Iwatsaki S, Griffith B P, Rosenthal J T, Hakala T R, Shaw B W, Hardesty R L, Atchinson R W, Jaffe R, Behnson H T. Reversibility of lymphomas and lymphoproliferative lesions developing under eyelosporin-steroid therapy. Lancet 1984; 1: 583
   PubMed Web of Science ®Google Scholar
• Leblond V, Davi F, Charlotte F, Dorent R, Ritker M O, Sutton L, Gandjbakhch I, Binet J L, Raphael M. Posttransplant lymphoproliferative disorders not associated with Epstein-Barr virus: a distinct entity?. Journal of Clinical Oncology 1998; 16: 2052
   PubMed Web of Science ®Google Scholar
• Dotti G, Fiocchi R, Motta T, Gamba A, Gotti E, Gridelli R, Borleri Manzoni G. C, Viero P, Remuzzi G, Barbui T, Rambaldi A. Epstein-Barr virus-negative lymphoproliferate disorders in long-term survivors after heart, kidney, and liver transplant [see comments]. Transplantation 2000; 69: 827
   PubMed Web of Science ®Google Scholar
• Rooney C M, Loftin S K, Holladay M S, Brenner M K, Krance R A, Heslop H E. Early identification of Epstein-Barr virus-associated post-transplant lymphoproliferative disease. Br J Haematol 1995; 89: 89
   Web of Science ®Google Scholar
• Riddler S A, Breinig M, Mc C., Knight J LC. Increased levels of circulating Epstein-Barr virus (EBV)-infected lymphocytes and decreased EBV nuclear antigen antibody responses are associated with the development of posttransplant lymphoproliferative disease in solid-organ transplant recipients. Blood 1901; 84: 972
   Google Scholar
• Savoie A, Perpete Carpentier C., Joncas L., Alfieri J. C. Direct correlation between the load of Epstein-Barr virus-infected lymphocytes in the peripheral blood of pediatric transplant patients and risk of lymphoproliferative disease. Blood 1904; 83: 2715
   Google Scholar
• Baldanti F, Grossi P, Furione M, Simoncini Sarasini L. A, Comoli P, Maccario R, Fiocchi R, Gerna G. High levels of Epstein-Barr virus DNA in blood of solid-organ transplant recipients and their value in predicting posttransplant lymphoproliferative disorders. J Clin Microbiol 2000; 38: 613
   PubMed Web of Science ®Google Scholar
• Green M, Cacciarelli T V, Maza-Iegos G V, Sigurdsson L, Qu L, Rowe D T, Reyes J. Serial measurement of Epstein-Barr viral load in peripheral blood in pediatric liver transplant recipients during treatment for posttransplant lymphoproliferative disease. Transplantation 1998; 66: 1641
   PubMed Web of Science ®Google Scholar
• Babcock G J, Decker L L, Freeman R B, Thorley-Lawson D A. Epstein-barr virus-infected resting memory B cells, not proliferating lymphoblasts, accumulate in the peripheral blood of immunosuppressed patients. J Exp Med 1999; 190: 567
   PubMed Web of Science ®Google Scholar
• Orazi A, Hromas R A, Neiman R S, Greiner T C, Lee C H, Rubin Haskins L. S, Heerema N A, Ghapure Abonour V. R., Srour E F, Cornetta K. Posttransplantation lymphoproliferative disorders in bone marrow transplant recipients are aggressive diseases with a high incidence of adverse histologic end immunobiologic features. Am J Clin Path 1997; 107: 419
   PubMed Web of Science ®Google Scholar
• Heslop H E, Li C, Krance R A, Loftin S K, Rooney C M. Epstein-Barr infection after bone marrow transplantation. Blood 1991; 83: 1706
   Google Scholar
• Darenkov I A, Marcarelli M A, Basadonna G P, Friedman A L, Lorber K M, How J G, Crouch J, Bia M J, Kliger A S, Lorber M I. Reduced incidence of Epstein-Barr virus-assocriated postransplant lymphoproliferaitive disorder us ng preemptive antiviral therapy. Transplantation 1997; 64: 848
   PubMed Web of Science ®Google Scholar
• Shapiro R S, McClain K, Frizzera G, Gajl-Peczalska K J, Kerscy J H, Blazar B R, Arthur D C, Patton D F, Greenberg J S, Burke B., Ramsay N KC, McGlave P, Filipovich A H. Epstein-Barr virus associated B cell lymphoproliferative disorders following bone marrow transplantation. Blood 1988; 71: 1234
   PubMed Web of Science ®Google Scholar
• Benkerrou M, Jais J P, Leblond V, Durandy A, Sutton L, Bordigoni P, Gamier J L, Le Bidois Le J., Deist F, Blanche S, Fischcr A. Anti-B-cell monoclonal antibody treatment of severe posttransplant B- lymphoproliferative disorder: prognostic factors and long-term outcome. Blood 1998; 92: 3137
   PubMed Web of Science ®Google Scholar
• Cook R C, Connors J M, Gascoyne R D, Fradet G, Levy R D. Treatment of post-transplant lymphoproliferative disease with rituximab monoclonal antibody after lung transplantation [letter]. Lancet 1999; 354: 1608
   PubMed Web of Science ®Google Scholar
• Milpied N, Vasseur B, Parquet N, Garnier J L, Antoine C, Quertier P, Carret A S, Bouscary D, Fuyc A, Bourbigot B, Reguerre Y, Stoppa A M, Bourquard P, de Ligny B H, Dubicl F. Mathieu-Boue A, Lehlond V Humanized anti-CD20 monoclonal antibody (Rituximab) in post transplant B-lymphoproliferaitive disorder: a retrospective analysis on 32 patients [In Process Citation]. Ann Oncol 11 Suppl 2000; 1: 113
   Web of Science ®Google Scholar
• Kuchnle I, Huls M H, Liu Z, Semmelmann M, Krance R A, Brenner M K, Rooney C M, Heslop H E. CD20 monoclonal antibody (rituximab) for therapy of Epstein Barr virus lymphoma after hemopoictic stem-cell transplantaton. Blool 2000; 95: 1502
   PubMed Web of Science ®Google Scholar
• McGuirk J P, Seropian S, Howe G, Smith B, Stoddart L, Cooper D L. Use of rituximab and irradiated donor-derived lymphoeytes to control Epstein-Barr virus-associated lymphoproliferation in patients undergoing related haplo-identical stem cell transplantation. Bone Marrow Transplant. 1999; 24: 1253
   PubMed Web of Science ®Google Scholar
• Davis T A., Czerwinshi D K, Levy R. Therapy of B-cell lymphoma with anti-CD20 antibodies can result in the loss of CD20 antigen expression [In Process Citation]. Clin Cancer Res 1999; 5: 611
   PubMed Web of Science ®Google Scholar
• Swinnen L J. Treatment of organ transplant-related lymphoma. Hematol Oncol Clin North Am 1999; 11: 963
   Web of Science ®Google Scholar
• Bourgault Gomez I. A, Gomard E., Levy J P. Limiting-dilution analysis of the HLA restriction of anti-Epstein-Barr virus-specific cytolytic T lymphocytes. Clin Exp Immunol 1991; 84: 501
   PubMed Web of Science ®Google Scholar
• Rencher S D, Slobod K S, Smith F S, Hurwitz J L. Activity of transplanted CD8+ versus CD4+ cytotoxic T cells against Epstein-Barr vinis-inmmortalized B cell tumors in SCID mice. Transplantation 1994; 58: 629
   PubMed Web of Science ®Google Scholar
• Papadopoulos E B, Ladanyi M, Emanuel D, MacKinnon S, Boulad F, Carabasi M H, Castro-Malaspina H, Childs B H, Gillio A P, Small T N, Young J W, Kernan N, O'Reilly R J. Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after alloge-neic bone marrow transplantation. N. Engl. J. Med. 1994; 330: 1185
   PubMed Web of Science ®Google Scholar
• Heslop H E, Brenner M K, Rooney C M. Donor T cells to treat EBV-associated lymphoma. N Engl J Med 1994; 331: 679
   PubMed Web of Science ®Google Scholar
• Riddell S R, Watanabe K S, Goodrich J M, Li C R, Agha M E, Greenbeg P D. Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones. Science 1992; 257: 238
   PubMed Web of Science ®Google Scholar
• Walter E A, Greenberg P D, Gilbert M J, Finch R J, Watanabe K S, Thomas E D, Riddell S R. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic hone marrow by transfer of T-cell clones from the donor. N Engl J Med 1995; 333: 1038
   PubMed Web of Science ®Google Scholar
• Rooney C M, Smith C A, Ng C, Loftin S, Li K. C, Krance R A, Brenner M K, Heslop H E. Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr virus-related lymphoproliferation. Lancet 1995; 345: 9
   PubMed Web of Science ®Google Scholar
• Smith C A, Ng C YC, Heslop H E, Holladay M S, Richardson S, Turner E V, Loftin S K, Li C., Brenner M K, Rooney C M. Production of genetically modified EBV-specific cytotoxic T cells for adoptive transfer to patients at high risk of EBV-associated lymphoproliferative disease. J Hematother 1995; 4: 73
   PubMedGoogle Scholar
• Heslop H E, Ng C YC, Li C, Smith C A, Loftin S K, Krance R A, Brenner M K, Rooney C M. Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes. Nature Medicine 1996; 2: 551
   PubMed Web of Science ®Google Scholar
• Rooney C M, Smith C A, Ng C YC, Loftin S K, Sixbey J W, Gan Y-J, Srivastava D-K, Bowman L C, Krance R A, Brenner M K, Heslop H E. Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients. Blood 1998; 92: 1549
   PubMed Web of Science ®Google Scholar
• Gustafsson A, Levitsky V, Zou J Z, Frisan T, Dalianis T, Ljungman P, Ringden O, Winiarski Ernberg J. I, Masucci M G. Epstein-Barr virus (EBV) load in hone marrow transplant recipients at risk to develop posttransplant lymphoproliferative disease: prophylactic infusion of EBV-specific cytotoxic T cells. Blood 2000; 95: 807
   PubMed Web of Science ®Google Scholar
• Gottschalk S, Ng C YC, Perez M, Brenner M K, Heslop H E, Rooney C M. Mutation in EBV produces immunoblastic lymphoma unresponsive to CTL immunotherapy. Blood 1998; 92: 321a, abstr.
   Web of Science ®Google Scholar
• Khanna R, Bell S, Sherritt M, Galbraith A, Burrows S R, Rafter L, Clarke B, Slaughter R, Falk M C, Dough J, Williams T, Elliott S L, Moss D J. Activation and adopt transfer of Epstein-Barr virus-specific cytotoxic T cells in solid organ transplant patients with posttransplant lymphoproliferative disease. Proc Natl Acad Sci U S A 1999; 96: 10391
   PubMed Web of Science ®Google Scholar
• Haque T., Amlot P L, Helling N, Thomas J A, Sweny Rolles P. K, Burroughs A K, Prentice H G, Crawford D H. Reconstitution of EBV-specific T cell immunity in solid organ transplant recipients. J Immunol 1998; 160: 6204
   PubMed Web of Science ®Google Scholar
• Nalesnik M A, Rao A S, Furukawa H, Pham S, Zeevi A, Fung J J, Klein G, Grittsch H A, Elder E, Whiteside T L, Starzl T E. Autologous lymphokine-activated killer cell therapy of Epstein-Barr virus-positive and -negative lymphoproliferative disorders arising in organ transplant recipients. Transplantation 1998; 63: 1200
   Web of Science ®Google Scholar
• Emanuel D J, Lucas K G, Mallory G B, Edwards-Brown M K, Pollok K E, Conrad P D, Robertson K A, Smith F O. Treatment of posttransplant lymphoproliferative disease in the central nervous system of a lung trasnplant recipient using allogeneic leucocytes. Transplantation 1997; 63: 1691
   PubMed Web of Science ®Google Scholar
• Yang J, Lemas V M, Flinn I W, Krone C, Ambinder R F. Application of the ELISPOT assay to the characterization of CD8(+) responses to Epstein-Barr virus antigens. Blood 2000; 95: 241
   PubMed Web of Science ®Google Scholar
• Orentas R J, Lemas M V, Mullin M J, Colombani P M, Schwartz K, Ambinder R. Feasibility of cellular adoptive immunotherapy for Epstein-Barr virus-associated lymphomas using haploidentical donors. J Hematother 1998; 7: 257
   PubMedGoogle Scholar
• O'Reilly R J, Small T N, Papadopoulos E, Lucas K, Lacerda J, Koulova L. Adoptive immunotherapy for Epstein-Barr virus-associated lymphoproliferative disorders complicating marrow allografts. Springer Semin Immunopathol 1998; 20: 455
   PubMed Web of Science ®Google Scholar
• Subklewe M, Chahroudi A, Schmaljohn A, Kurilla M G, Bhardwaj N, Steinman R M. Induction of Epstein-Barr virus-specific cytotoxic T-lymphocyte responses using dendritic cells pulsed with EBNA-3A peptides or UV-inactivated. recombinant EBNA-3A vaccinia virus. Blood 1999; 94: 1372
   Google Scholar
• Boyle G J, Michaels M G, Webber S A, Knisely A S, Kurland G, Cipriani L A, Griffith B P, Fricker F J. Posttransplantation lymphoproliferative disorders in pediatric thoracic organ recipients. J Pediatr 1997; 131: 309
   PubMed Web of Science ®Google Scholar
• Curtis R E, Travis L B, Rowlings P A, Socie G, Kingma D W, Banks P M, Jaffe E S, Sale G E, Horowitz M M, Witherspoon R P, Shriner D A, Weisdorf D J, Kolb H J, Sullivan K M, Sohcr-Inski K A, Gale R P, Hoover R N, Fraumeni J F, Jr., Deeg H I. Risk of lymphoproliferative disorders after bone marrow transplantation: a multi-institutional study. Blood 1999; 94: 2208
   PubMed Web of Science ®Google Scholar
• Hale G, Waldmann H, for CAMPATH users. Risks of developing Epstein-Barr virus-related lymphoproliferative disorders after T-cell-depleted marrow transplants. Blond 1998; 91: 3079
   PubMed Web of Science ®Google Scholar